Skip to main content

PepGen Inc.

corporate_fare Company Profile

PepGen Inc.

PEPG·NASDAQ·Life Sciences·CIK 0001835597

PepGen Inc. is a clinical-stage biotechnology company focused on developing advanced oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides (CPPs) to improve how conjugated oligonucleotide therapeutics are absorbed and become active. These EDO peptides are designed to optimize tissue penetration, cellular uptake, and delivery to the cell nucleus. Preclinical studies have shown they can transport oligonucleotides into various target tissues, including smooth, skeletal, and cardiac muscle. Clinical trials have demonstrated strong delivery and activity of oligonucleotides in skeletal muscle. PepGen is currently addressing myotonic dystrophy type 1 (DM1), a multi-systemic neuromuscular disease with no approved therapies. The company is developing PGN-EDODM1 for DM1. PGN-EDODM1's therapeutic oligonucleotide component is engineered to bind to the pathogenic cytosine-uracil-guanine (CUG) repeat expansion in the myotonic dystrophy protein kinase (DMPK) messenger RNA (mRNA) of DM1 patients. By binding to these expanded repeats, PGN-EDODM1 reduces their ability to sequester RNA binding proteins like MBNL1, a key RNA splicing factor. This liberation of MBNL1 corrects downstream mis-splicing events that cause DM1 pathology. The company anticipates expanding the EDO technology to other severe diseases with significant unmet needs.

PepGen Inc. (NASDAQ:PEPG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for PEPG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for PEPG spans 4, 10-Q, 8-K, S-3.

Recent high-impact activity:

  • RA Capital Buys $43.1M of PepGen Stock at the $5.00 Offering Price
  • PepGen Prices $125M Offering at $5.00, a Discount to Tuesday's Close
  • PepGen Seeks $125M Equity Raise Hours After Positive Phase 2 Data
  • PepGen Q3 Cash Falls to $104.8M; Runway Extended Into 2028 on FREEDOM2 Data
  • PepGen's DM1 Drug Hits 46.5% Splicing Correction in Phase 2, Best Reported to Date

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$89.66M
Diluted EPS
-$2.12
Op. Cash Flow
-$81.64M
Free Cash Flow
-$81.9M
Operating Income
-$93.61M
Cash & Equivalents
$60.51M
Debt / Equity
0.00×
Shares Outstanding
68.87M sh
Source: 10-K · filed 2026-03-04 · accession 0001193125-26-091536

Short Interest & Short Volume

2.83 days to cover

FINRA reported short interest of 3,367,041 shares in PEPG as of the October 30, 2026 settlement, a 11.5% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 52.0% of PEPG volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,367,041 shares as of October 30, 2026
Change vs prior period▼ 11.5%
Days to cover2.83 at avg daily volume of 1,190,755
Daily short volume (FINRA facilities)52.0% of 2,262,970 shares on November 20, 2026
5-day average short volume36.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PEPG, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.

1 recent capital raise

Preliminary Terms for $125M Offering · Underwriters and 30-Day Option

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$3.79 +0.26% today
52-week range · as of 2026-11-17 $1.31 – $7.8
Market cap
$261.81M
Volume
4.4M (0.7× avg)
3-mo avg 6.1M
Live data · 2026-11-21 07:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PEPG - Latest Insights

PEPG
Nov 17, 2026, 4:07 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $3.89
Real-time Price: $3.79 info
Change: -$0.100 (-3%) info
Market Cap: $261.808M info
PEPG
Nov 11, 2026, 10:22 PM EST
Source: BusinessWire
Importance Score:
7
Updated Nov 12, 4:34 PM ET — PepGen's 25M-share offering at $5.00 yields $117.5M net proceeds before expenses, with a 30-day option for 3.75M more shares and closing ex…
Price at Filing: $5.35
Real-time Price: $3.79 info
Change: -$1.56 (-29%) info
Market Cap: $261.808M info
PEPG
Nov 10, 2026, 4:23 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $4.89
Real-time Price: $3.79 info
Change: -$1.09 (-22%) info
Market Cap: $261.808M info
PEPG
Nov 10, 2026, 7:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $3.79 info
Change: +$1.39 (+58%) info
Market Cap: $261.808M info
PEPG
Nov 10, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $3.79 info
Change: +$1.39 (+58%) info
Market Cap: $261.808M info
PEPG
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $3.79 info
Change: +$0.990 (+35%) info
Market Cap: $261.808M info
PEPG
Aug 06, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.10
Real-time Price: $3.79 info
Change: +$1.69 (+80%) info
Market Cap: $261.808M info
PEPG
Aug 06, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $3.79 info
Change: +$1.64 (+76%) info
Market Cap: $261.808M info
PEPG
Aug 06, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $1.96
Real-time Price: $3.79 info
Change: +$1.83 (+93%) info
Market Cap: $261.808M info
PEPG
May 21, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $3.79 info
Change: +$2.34 (+161%) info
Market Cap: $261.808M info
PEPG
May 19, 2026, 12:03 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.41
Real-time Price: $3.79 info
Change: +$2.38 (+169%) info
Market Cap: $261.808M info
PEPG
May 12, 2026, 4:11 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.67
Real-time Price: $3.79 info
Change: +$2.12 (+127%) info
Market Cap: $261.808M info
PEPG
May 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.67
Real-time Price: $3.79 info
Change: +$2.12 (+127%) info
Market Cap: $261.808M info
PEPG
May 12, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.67
Real-time Price: $3.79 info
Change: +$2.12 (+127%) info
Market Cap: $261.808M info
PEPG
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $3.79 info
Change: +$2.21 (+140%) info
Market Cap: $261.808M info
PEPG
Mar 30, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.18
Real-time Price: $3.79 info
Change: +$1.61 (+74%) info
Market Cap: $261.808M info
PEPG
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $3.79 info
Change: +$1.43 (+61%) info
Market Cap: $261.808M info
PEPG
Mar 04, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.58
Real-time Price: $3.79 info
Change: -$1.79 (-32%) info
Market Cap: $261.808M info
PEPG
Mar 04, 2026, 4:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $5.60
Real-time Price: $3.79 info
Change: -$1.81 (-32%) info
Market Cap: $261.808M info
PEPG
Mar 04, 2026, 4:28 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $4.94
Real-time Price: $3.79 info
Change: -$1.15 (-23%) info
Market Cap: $261.808M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets